Based on the cell death-promoting effect of TNFR1-complex II, the potency of human recombinant TNF-α as an anti-tumor therapy was tested in numerous clinical trials but declined owing to the unclear role of the TNFR1-mediated signaling pathway in cancer 6. Here, TNFRSF1A is linked to neoplasm.